תבנית:תרופה/טבעפירין - Tevapirin

×©××× ××Â !
××ª×¨××¤× ×× × ××¦××ª ×-××××¨ ××ª×¨××¤××ª ×©× ××©×¨× ×××¨××××ª.
×¦×¤× ××××××© ××©××××§ "×¢× ×××××¢× ×××©×", ×¨×× ××××¢× ××ª×××× ×-××¢×¨××ª ×××××¢××ª ×¢× ××¤×¡×§×ª ×©××××§ ×ª×¨××¤××ª.
×ª××¨×× ×××××¢× ××× 7.4.2021.

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×§×××¦× ×¤×¨××§××××××ª (ATC4)	B01AC Platelet aggregation inhibitors excluding heparin
××¨××× ×¤×¢×× (ATC5)	Â Acetylsalicylic acid 100MG âB01AC06
×¦××¨×ª ××ª×	×¤××× - PER OS
×¦××¨×ª ××× ××	××××××ª ×¢× ×¦××¤×× ×× ××¨×, TABLETS ENTERIC COATED ××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××
××ª××××	The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
×ª×× ××ª:× ×ª×× × ×¡×/×ª×¨××¤×/×××¢×¤××¨×× - Tevapirin
×¢××× ××¨××¤× ×××××¨××ª ××¢×××	××× ×¢××× ××¨××¤× Â ××××¨× ××¢××× 06.01.2022 ××××¨× ××¢××× 30.11.2020 ××××¨× ××¢××× ××¨××¤× 31.03.2018

×¢××× ××¦×¨××	Â ×¢××× ××¦×¨×× ×¢××¨××ª 06.01.2022 ×¢××× ××¦×¨×× ×× ××××ª Patient information leaflet â06.01.2022 ×¢××× ××¦×¨×× ×¢×¨×××ª ÙØ´Ø±Ø© ÙÙÙØ³ØªÙÙÙ Ø¨Ø§ÙÙØºØ© Ø§ÙØ¹Ø±Ø¨ÙØ© 06.01.2022 ×¢××× ××¦×¨×× ×¨××¡××ª Ð¸Ð½ÑÑÑÑÐºÑÐ¸Ñ Ðº Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ Ð´Ð»Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² â06.01.2022

×¢××× ××¦×¨××

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×××¢×¤××¨×× ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	-
××××¢ ××¨×©×ª	-
×©× ××¦×¨×	TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
×©× ××¢× ××¨××©××	TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
×¨××©×××	×ª××¨×× ×××©×: 3/2014. ×¨××©××× ××ª××¨××: 07/2014
×ª××¨×× ×¢×××× ×××¨××	7.4.2021

×ª××× ×ª ××¨×××

×ª××× ×ª ××¨×××

××£ ×× × ××¦×¨ ×¢× ××× ××× ××××××¨ ×ª×× ××ª ×¢× ×¤×¨×× ××ª×¨××¤×.

{{×ª×¨××¤×/×××¢×¤××¨×× - Tevapirin}}

×:

{{×ª×¨××¤×/×××¢×¤××¨×× - Tevapirin
| ×©× ××¤×¨×××¨=×¢×¨× ×××© (×××¨×¡ ××ª ××¢×¨× ×©×××× ×××××¨)
}}

השינוי האחרון נעשה בֹ־29 בפברואר 2024 ב־22:31

ויקיתרופות